Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G W Carter

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
European Journal of Pharmacology|April 23, 1997
Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonistD H Albert, T J Magoc, P Tapang, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitisD H Albert, P E Malo, P Tapang, et al.
Journal of Medicinal Chemistry|February 26, 2000
Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitorsT Kolasa, D E Gunn, P Bhatia, et al.
Journal of Medicinal Chemistry|September 1, 2000
Symmetrical bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as inhibitors of leukotriene biosynthesisT Kolasa, D E Gunn, P Bhatia, et al.
The Journal of Biological Chemistry|October 11, 2001
Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compoundsJ M Trevillyan, X G Chiou, Y W Chen, et al.
The Journal of Investigative Dermatology|May 8, 1999
A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseasesK W Mollison, T A Fey, D M Gauvin, et al.
Biorxiv : the Preprint Server for Biology|June 29, 2026
Molecular mechanisms underlying amyloid lowering by aducanumab: differential and comparative effects of sex and IgG reveal the post-treatment disease brainK A Haynes, R S Pandey, E H Doud, et al.
Journal of Medicinal Chemistry|June 20, 1997
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitorsA O Stewart, P A Bhatia, J G Martin, et al.
Journal of Medicinal Chemistry|August 24, 2000
3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulatorS W Djuric, N Y BaMaung, A Basha, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
European Journal of Pharmacology|April 23, 1997
Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonistD H Albert, T J Magoc, P Tapang, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitisD H Albert, P E Malo, P Tapang, et al.
Journal of Medicinal Chemistry|February 26, 2000
Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitorsT Kolasa, D E Gunn, P Bhatia, et al.
Journal of Medicinal Chemistry|September 1, 2000
Symmetrical bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as inhibitors of leukotriene biosynthesisT Kolasa, D E Gunn, P Bhatia, et al.
The Journal of Biological Chemistry|October 11, 2001
Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compoundsJ M Trevillyan, X G Chiou, Y W Chen, et al.
The Journal of Investigative Dermatology|May 8, 1999
A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseasesK W Mollison, T A Fey, D M Gauvin, et al.
Biorxiv : the Preprint Server for Biology|June 29, 2026
Molecular mechanisms underlying amyloid lowering by aducanumab: differential and comparative effects of sex and IgG reveal the post-treatment disease brainK A Haynes, R S Pandey, E H Doud, et al.
Journal of Medicinal Chemistry|June 20, 1997
Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitorsA O Stewart, P A Bhatia, J G Martin, et al.
Journal of Medicinal Chemistry|August 24, 2000
3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulatorS W Djuric, N Y BaMaung, A Basha, et al.
Pageof 8